Mevion Medical Systems Delivers the MEVION S250 Superconducting Synchrocyclotron to Robert Wood Johnson University Hospital
Mevion Medical SystemsMelanie M. Miller, 978-540-1551Marketing & Communications CoordinatororRobert Wood Johnson University HospitalPeter Haigney or Zenaida Mendez, 732-937-8521
announced today that it has delivered the superconducting synchrocyclotron for the MEVION S250 Proton Therapy System currently under installation at Robert Wood Johnson University Hospital in New Brunswick, NJ, the flagship cancer hospital of The Cancer Institute of New Jersey and the principal teaching hospital of UMDNJ-Robert Wood Johnson Medical School. This is the second MEVION S250 proton therapy system delivered in the past 6 months, both installed at NCI-designated Comprehensive Cancer Centers.
Powered by a TriNiobium Core™, the is a modern and first-of-its-kind proton therapy system that provides the same precise, non-invasive treatment capabilities and advantages of complex, large, and costly proton therapy systems but with a significantly reduced footprint, improved reliability, more advanced clinical systems, and lower implementation and operational costs. “Robert Wood Johnson University Hospital has a proud history of clinical innovation and a commitment to provide the highest quality and value of services to its patients and community,” says Stephen K. Jones, FACHE, President and Chief Executive Officer, Robert Wood Johnson University Hospital and Robert Wood Johnson Health System. “We are excited to be the first in the northeast to receive this revolutionary technology and add this innovative proton therapy service to our comprehensive list of cancer services.”
In addition to offering proton beam therapy and Gamma Knife Perfexion™ for the treatment of brain tumors, The Cancer Hospital at RWJUH is the flagship hospital of The Cancer Institute of New Jersey (CINJ), the state’s only National Cancer Institute-designated Comprehensive Cancer Center and the hospital’s cancer program has been accredited by the American College of Surgeons’ Commission on Cancer. The partnership between RWJUH, UMDNJ-RWJMS and CINJ offers patients a unique opportunity to benefit from clinical research performed at CINJ while receiving expert care from faculty and community physicians in a state-of-the-art environment at RWJUH. RWJUH’s cancer program was recently ranked among the top 50 programs in the United States by U.S.News & World Report as part of its 2012 ranking of “America’s Best Hospitals.”
Manufactured in Massachusetts, it took only one day for the MEVION S250 accelerator to travel to New Jersey and only a few hours to be brought inside the proton center. “The proton therapy modernization and size reduction that we deliver today has redefined the economics and accessibility of proton therapy,” says Joseph K. Jachinowski, Chief Executive Officer of Mevion Medical Systems. “We are delighted to be entering this final installation phase of the MEVION S250 proton therapy system at another leading cancer hospital.”
The MEVION S250 has recently received United States Food and Drug Administration 510(k) clearance and CE Certification enabling Mevion customers to treat patients. With four centers under installation or construction and more than a dozen under planning, Mevion has quickly established itself as a leading proton therapy supplier worldwide.
Mevion Medical Systems, Inc. is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinical reality.
Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.
Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan.
Visit us at:
Robert Wood Johnson University Hospital (RWJUH) is a 600-bed academic medical center and the principal hospital of UMDNJ-Robert Wood Johnson Medical School in New Brunswick, NJ. Robert Wood Johnson is an innovative leader in advancing state-of-the-art care. RWJUH is the first hospital in the nation to implant the AbioCor self-contained artificial heart since the device received FDA approval in 2006. RWJUH is one of only three sites in the nation approved to offer this groundbreaking technology. Its Centers of Excellence include cardiovascular care from minimally invasive heart surgery to transplantation, cancer care, and women’s and children’s care including The Bristol-Myers Squibb Children’s Hospital at Robert Wood Johnson University Hospital (). The hospital is also a Level 1 Trauma Center and serves as a national resource in its ground-breaking approaches to emergency preparedness. The hospital has earned significant national recognition for clinical quality and patient safety. RWJUH ranks among the best hospitals in America, according to U.S.News & World Report’s 2011 ranking of “America’s Best Hospitals.” It is the fifth consecutive year that RWJUH has achieved this prestigious ranking. The Bristol-Myers Squibb Children’s Hospital is also ranked among the nation’s Best Children’s Hospitals by U.S.News & World Report. The American College of Surgeons’ Commission on Cancer has rated RWJUH among the nation's best comprehensive cancer centers. The Leapfrog Group rated RWJUH as one of the 50 exceptional U.S. hospitals, as published in Consumers Digest magazine, and has given the hospital an “A” grade for safety and quality. Harvard University researchers, in a study commissioned by The Commonwealth Fund, identified RWJUH as one of the top 10 hospitals in the nation for clinical quality. RWJUH is also a four-time recipient of the prestigious Magnet Award for Nursing Excellence. Visit us online at .
LPR120605